Alpha Crest Capital Management LLC Blueprint Medicines Corp Transaction History

Alpha Crest Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $67,555 - $105,128	1,353 Added 27.71%	6,236 $411,000
Q2 2022 Aug 11, 2022	SELL	$45.23 - $70.15 $116,874 - $181,267	-2,584 Reduced 34.61%	4,883 $247,000
Q1 2022 May 12, 2022	BUY	$54.1 - $110.08 $403,964 - $821,967	7,467 New	7,467 $477,000
Q3 2021 Nov 10, 2021	SELL	$80.98 - $109.47 $231,926 - $313,522	-2,864 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$82.78 - $101.0 $1.28 Million - $1.56 Million	-15,432 Reduced 84.35%	2,864 $252,000
Q1 2021 May 13, 2021	BUY	$90.71 - $108.28 $860,475 - $1.03 Million	9,486 Added 107.67%	18,296 $1.78 Million
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $811,224 - $1.1 Million	8,810 New	8,810 $988,000
Q2 2020 Aug 12, 2020	SELL	$57.09 - $79.27 $530,937 - $737,211	-9,300 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$48.11 - $82.22 $447,423 - $764,646	9,300 New	9,300 $544,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.